Facebook Tracking Image

National Comprehensive Cancer Network

About NCCN

NCCN Flash Updates: NCCN Guidelines® and NCCN Compendium® for B-Cell Lymphomas and New NCCN Templates®

NCCN has published updates to the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) and the NCCN Drugs & Biologics Compendium (NCCN Compendium®) for B-Cell Lymphomas These NCCN Guidelines® are currently available as Version 5.2019.

  • Global change
    • Rituximab-abbs and rituximab-pvvr are included as appropriate substitutes for rituximab in all subtypes of B-cell lymphomas with the following statement, “An FDA-approved biosimilar is an appropriate substitute for rituximab.”
  • The Discussion section has been updated to reflect the changes in the algorithm. (MS-1)

 

Previous updates to the NCCN Guidelines for B-Cell Lymphomas can be found in the UPDATES section of the current version.

 

NCCN has published NEW NCCN Chemotherapy Order Templates (NCCN Templates®) for Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma to reflect the currently published NCCN Guidelines for Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma v1.2020.

  • The following NEW NCCN Templates have been published:
    • CLL86: Ibrutinib + RiTUXimab
    • CLL87: Ibrutinib + Obinutuzumab
    • CLL88: Venetoclax + Obinutuzumab

 

NCCN has published NEW NCCN Templates® for Diffuse Large B-Cell Lymphoma to reflect the NCCN Guidelines for B-Cell Lymphomas v4.2019.

  • The following NEW NCCN Templates have been published:
    • DBL58: DHAX (Dexamethasone/Cytarabine/OXALIplatin) + RiTUXimab
    • DBL59: DHAX (Dexamethasone/Cytarabine/OXALIplatin)

 

For the complete updated versions of the NCCN Guidelines, NCCN Guidelines with NCCN Evidence Blocks™, the NCCN Drugs & Biologics Compendium (NCCN Compendium®), the NCCN Biomarkers Compendium®, the NCCN Chemotherapy Order Templates (NCCN Templates®), the NCCN Radiation Therapy Compendium™, and the NCCN Imaging Appropriate Use Criteria (NCCN Imaging AUC™), please visit NCCN.org.

To view the NCCN Guidelines for Patients®, please visit NCCN.org/patientguidelines.

Free NCCN Guidelines apps for iPhone, iPad, and Android smartphones & tablets are now available! Visit NCCN.org/apps

About NCCN Flash Updates™ 

NCCN Flash Updates™ is a subscription service from NCCN that provides timely notification of updated and new information appearing in the NCCN Guidelines, the NCCN Compendium®, and other NCCN Content. 

Subscribe to NCCN Flash Updates™ 

Please note: The NCCN Third Party Content FTP site: ftp://ftp1.nccn.org/ThirdPartyContent/ has been updated. Licensees are solely responsible for obtaining permission from such third party to use any such Third Party Content in the Permitted Works.

National Comprehensive Cancer Network® (NCCN®)

3025 Chemical Road, Suite 100

Plymouth Meeting, PA 19462

Telephone: +1 215.690.0300 Fax: +1 215.690.0280 

Access information on permissions and licensing of NCCN Content  

© 2019 National Comprehensive Cancer Network. All Rights Reserved.

Users may opt-out via e-mail or by updating their profile. Users may unsubscribe at any time by contacting us.

NOTE: The subscription fee for NCCN Flash Updates™ is non-refundable.